Oculis Announces Pricing of $40.25 Million Public Offering
ZUG, Switzerland and BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to...
Source: globenewswire.com
📰 Oculis Sa News
Oculis Sa News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Oculis Sa. Real-time updates on events, politics, business and more.
Press Release: Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development
Press Release: Oculis Strengthens its Scientific Advisory Board with World-Leading Ophthalmology Experts to Support Pipeline Development Oculis Strengthens its Scientific Advisory Board with World-Leading
Source: finanznachrichten.de
Oculis appoints Dr. Bastian Dehmel as Chief Development
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer Former Amgen Global Development Leader/OxThera CMO joins Oculis as Chief Development...
Source: globenewswire.com
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer
Oculis appoints Dr. Bastian Dehmel as Chief Development Officer - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com